23 completed, 7 terminated, 3 active not recruiting, 2 withdrawn. 36 Phase 1, 8 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 36 | Completed 23, Terminated 7, Active not recruiting 3, Withdrawn 2, Recruiting 1 |
| Phase 2 | 8 | Completed 5, Terminated 3 |
Follow Recurrent Melanoma: new trials by email Literature Review of Recurrent Melanoma trials Research Report on Recurrent Melanoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Aerosolized Sargramostim Added to Immunotherapy for the Treatment of Patients With Metastatic Melanoma to the Lung Aerosol Sargramostim, Biospecimen Collection, Computed Tomography - Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Malignant Neoplasm in the Lung | Phase 1 | Withdrawn | Mayo Clinic | 2025-10-28 | 2025-08-07 | |
| Phase 1 Dose Escalation and Expansion Study of PRAME T Cell Receptor (TCR) Engineered NK Cells in Participants With Recurrent and/or Refractory Melanoma (PRAMETIME-Mel) Cyclophosphamide, Fludarabine - Phase 1, Recurrent Melanoma | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 39 | 2025-02-25 | 2026-10-05 |
| Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV Biospecimen Collection, Cabozantinib S-malate, Computed Tomography - Advanced Differentiated Thyroid Gland Carcinoma, Advanced Head and Neck Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 8 | 2021-11-22 | 2026-05-28 |
| Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Colorectal Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 59 | 2015-04-08 | 2026-10-07 |
| Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas Ipilimumab, Laboratory Biomarker Analysis, Nivolumab - Metastatic Melanoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 140 | 2015-03-30 | 2023-10-17 |
| APN401 in Treating Patients With Melanoma, Kidney Cancer, Pancreatic Cancer, or Other Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery siRNA-transfected peripheral blood mononuclear cells APN401, laboratory biomarker analysis - Recurrent Melanoma, Recurrent Pancreatic Cancer | Phase 1 | Completed | Wake Forest University Health Sciences | 17 | 2014-12-01 | 2018-07-03 |
| Evaluating SINE KPT-330 in Treating Patients With Melanoma That Cannot Be Removed By Surgery selinexor, Correlative studies - Recurrent Melanoma | Phase 1 | Completed | Kari Kendra | 8 | 2014-08-22 | 2023-04-04 |
| Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery cabozantinib-s-malate, vemurafenib, laboratory biomarker analysis - Recurrent Melanoma, Stage IIIA Melanoma | Phase 1 | Terminated | National Cancer Institute (NCI) | 5 | 2013-05-01 | 2014-09-25 |
| Vaccine Therapy in Treating Patients With Advanced Stage III-IV Melanoma Recombinant Human Hsp110-gp100 Chaperone Complex Vaccine, Laboratory Biomarker Analysis - Recurrent Melanoma, Stage IIIB Skin Melanoma | Phase 1 | Terminated | Roswell Park Cancer Institute | 10 | 2013-03-26 | 2022-07-22 |
| Ipilimumab and Local Radiation for Selected Solid Tumors Ipilimumab, Radiation therapy - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 1 | Terminated | Stanford University | 3 | 2013-02-01 | 2024-01-24 |
| Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors Cabozantinib S-malate, Laboratory Biomarker Analysis, Pharmacological Study - Recurrent Malignant Solid Neoplasm, Recurrent Melanoma | Phase 1 | Completed | National Cancer Institute (NCI) | 41 | 2012-11-14 | 2023-12-22 |
| Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma Ipilimumab, Whole-Brain Radiation Therapy (WBRT), Stereotactic Radiosurgery (SRS) - Recurrent Melanoma, Stage IV Melanoma | Phase 1 | Completed | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 17 | 2012-11-09 | 2025-05-16 |
| Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction Pharmacological Study, Romidepsin - Glioma, Hematopoietic and Lymphoid Cell Neoplasm | Phase 1 | Completed | National Cancer Institute (NCI) | 37 | 2012-08-03 | 2025-02-07 |
| Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Laboratory Biomarker Analysis, Pharmacological Study - Anaplastic Astrocytoma, Anaplastic Oligoastrocytoma | Phase 1 | Completed | Roswell Park Cancer Institute | 18 | 2012-03-01 | 2016-10-04 |
| Vaccine Therapy Following Therapeutic Autologous Lymphocytes and Cyclophosphamide in Treating Patients With Metastatic Melanoma cyclophosphamide, aldesleukin, autologous tumor cell vaccine - Recurrent Melanoma, Stage IV Melanoma | Phase 1 | Completed | Fred Hutchinson Cancer Center | 12 | 2012-03-01 | 2014-04-21 |
| Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma Laboratory Biomarker Analysis, Pharmacological Study, Riluzole - Advanced Malignant Solid Neoplasm, Recurrent Melanoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 35 | 2011-02-18 | 2026-09-15 |
| RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer Cognitive Assessment, Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis - Adult Solid Neoplasm, Extensive Stage Lung Small Cell Carcinoma | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 5 | 2010-10-01 | 2024-11-19 |
| Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Combination With Cisplatin, Vinblastine, and Temozolomide in Treating Patients With Recurrent or Metastatic Melanoma Cisplatin, Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis - Recurrent Melanoma, Stage IV Skin Melanoma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 14 | 2010-08-01 | 2019-11-18 |
| Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors Gamma-Secretase Inhibitor RO4929097, Cediranib Maleate, Pharmacological Study - Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma | Phase 1 | Completed | National Cancer Institute (NCI) | 20 | 2010-05-01 | 2014-12-23 |
| Tremelimumab and CP-870,893 in Patients With Metastatic Melanoma CD40 agonist monoclonal antibody CP-870,893, tremelimumab, laboratory biomarker analysis - Recurrent Melanoma, Stage IV Melanoma | Phase 1 | Completed | Abramson Cancer Center at Penn Medicine | 25 | 2010-02-01 | 2020-04-07 |
Showing 20 of 36. Sign in to see all of them.
Melanoma (36) · Carcinoma, Renal Cell (10) · Breast Neoplasms (6) · Brain Neoplasms (5) · Carcinoma, Non-Small-Cell Lung (5) · Breast Neoplasms, Male (4) · Colonic Neoplasms (4) · Ovarian Neoplasms (4) · Prostatic Neoplasms (4) · Astrocytoma (3) · Carcinoma, Medullary (3) · Colorectal Neoplasms (3) · Lung Neoplasms (3) · Neoplasm Metastasis (3) · Pancreatic Neoplasms (3)
Neoplasms by Histologic Type (36) · Neoplasms by Site (36) · Neoplasms, Germ Cell and Embryonal (36) · Neoplasms, Nerve Tissue (36) · Neuroectodermal Tumors (36) · Nevi and Melanomas (36) · Skin Diseases (36) · Skin and Connective Tissue Diseases (36) · Neoplasms (35) · Neuroendocrine Tumors (35) · Skin Neoplasms (35) · Neoplasms, Glandular and Epithelial (14) · Female Urogenital Diseases (13) · Female Urogenital Diseases and Pregnancy Complications (13) · Urogenital Diseases (13)
Cyclophosphamide (6) · Biopsy (5) · Immunohistochemistry (5) · Interleukin-2 (5) · Ipilimumab (5) · Polymerase Chain Reaction (5) · aldesleukin (5) · CTLA-4 Antigen (4) · 2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide (3) · Nivolumab (3) · Radiosurgery (3) · Sirolimus (3) · Specimen Handling (3) · cabozantinib (3) · Immunologic Techniques (2)
National Cancer Institute (NCI) (19) · Fred Hutchinson Cancer Center (4) · Mayo Clinic (2) · Roswell Park Cancer Institute (2) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (2) · Abramson Cancer Center at Penn Medicine (1) · Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium (1) · Kari Kendra (1) · M.D. Anderson Cancer Center (1) · National Heart, Lung, and Blood Institute (NHLBI) (1) · Stanford University (1) · Wake Forest University Health Sciences (1)
United States (34) · Canada (5)
Cassian Yee (2) · Sylvia Lee (2) · Wenyin Shi, MD, PhD (2) · Aude Chapuis (1) · Crystal L Mackall (1) · David Solit (1) · Frank Hodi (1) · Frank S Hodi (1) · Gary Hudes (1) · George A. Fisher, MD, PhD (1) · Haiying Cheng (1) · Isabella C Glitza Oliva, MD (1) · Janice M Mehnert (1) · Jason Luke (1) · Jeffrey Weber (1)
PMID 27269940, PMID 28816150, PMID 31401903, PMID 32192573, PMID 35264434, PMID 37036756, PMID 38236249, PMID 39863139, PMID 40132910, PMID 42847673
K12CA076930 (3), P30CA016672 (2), U01CA062490 (2), U01CA062505 (2), U01CA069856 (2), U01CA132123 (2), UM1CA097452 (2), UM1CA186644 (2), UM1CA186709 (2), UM1CA186716 (2), N01CM00039 (1), N01CM62202 (1), N01CM62206 (1), P30CA006516 (1), P30CA008748 (1)